Starting Treatment Early for Metastatic Prostate Cancer: Part II

In 2010 the FDA approved Provenge for hormone-refractory prostate cancer. Provenge is a treatment that functions by enhancing the immune system. Some critics have called the effectiveness of Provenge into question because the effectiveness of most cancer treatments is reflected in a PSA decline after treatment. However, with Provenge therapy PSA levels usually do not drop. Having personally supervised several hundred Provenge-treated men, I have observed exceptional cases in which Provenge lowers PSA.  READ THE FULL ARTICLE HERE >

Leave a Reply

Your email address will not be published. Required fields are marked *